Highest-materiality recent filing
Q2 revenue $71.6M (+22% YoY); MRD revenue $66.2M (+33% YoY); clonoSEQ volume 36,111 (+43% YoY).
Adaptive Biotech prices $345M 0% convertible notes; repays OrbiMed, repurchases $25M stock
Issued $345M 0% convertible notes due 2031; net proceeds ~$334.5M after discounts and expenses.
Adaptive Biotechnologies proposes $250M notes offering, plans MRD/Immune Medicine separation
Intends to issue $250M convertible senior notes due 2031 (plus $37.5M option) to qualified institutional buyers.
Q1 revenue $70.9M (+35% YoY); MRD revenue $67.1M (+53% YoY); clonoSEQ test volume 32,595 (+41%).
Adaptive Biotechnologies Q4 rev $71.7M (+51% YoY); MRD profitable; FY2026 MRD rev guide $255-265M
Q4 revenue $71.7M (+51% YoY); FY revenue $277.0M (+55% YoY); net loss narrowed to $13.6M and $59.5M.
Adaptive Biotechnologies reports preliminary Q4/FY2025 revenue growth of 51%/55% YoY
Total revenue FY2025 ~$277M (+55% YoY); Q4 ~$72M (+51% YoY).
Adaptive Biotechnologies Q3 revenue $94M (+102% YoY); MRD profitable, guidance raised
Revenue $94.0M (up 102% YoY) includes $33.7M from full amortization of Genentech payment.
Adaptive and Genentech terminate cell therapy collaboration; $33.7M non-cash revenue in H2 2025
Strategic Collaboration and License Agreement with Genentech terminated Aug 13, 2025; effective Feb 9, 2026.
Adaptive Q2 MRD revenue up 42%, achieves MRD profitability; raises FY guidance
Total revenue $58.9M (+36% YoY); MRD revenue $49.9M (+42% YoY); MRD Adjusted EBITDA positive $1.9M.
Adaptive Biotechnologies Q1 revenue up 25% to $52.4M; raises MRD guidance
Q1 revenue $52.4M (+25% YoY); MRD revenue $43.7M (+34%); clonoSEQ volume up 36% to 23,117 tests.
Adaptive Biotech Q4 revenue $47.5M; MRD revenue up 31% YoY; FY2025 MRD guidance $175-185M
Q4 total revenue $47.5M (+4% YoY); full year $179.0M (+5%). MRD revenue $40.1M (+31% Q4, +42% FY).
Adaptive Biotechnologies Q3 revenue $46.4M (+22%); MRD revenue up 52%; net loss narrows to $32.1M
Revenue $46.4M (+22% YoY); MRD revenue $37.5M (+52%); Immune Medicine $9.0M (-32%).
Adaptive Biotechnologies Q2 MRD revenue up 36% YoY; updates FY guidance
Total Q2 revenue $43.2M (-12% YoY); MRD revenue $35.3M (+36%), Immune Medicine $7.9M (-66%).
Adaptive Biotechnologies Q1 2024: MRD revenue up 52% to $32.6M; net loss narrows to $47.5M
Total revenue $41.9M (+11% YoY); MRD $32.6M (+52%), Immune Medicine $9.2M (-43%).
Adaptive Biotechnologies appoints Kyle Piskel as CFO effective April 8, 2024
Kyle Piskel promoted from Principal Accounting Officer to CFO; reports to CEO Chad Robins.
Adaptive Biotech Q1 prelim rev ~$41-43M (+12% YoY); CFO Peterson departs, Piskel named
Preliminary total Q1 2024 revenue of ~$41-43M, up ~12% vs Q1 2023.
Adaptive Biotech Q4 revenue down 17% to $45.8M; net loss widens to $69.5M
Full year 2023 revenue $170.3M (-8% YoY); MRD revenue $102.7M (+18%) offset by IM decline.
Adaptive Biotechnologies Q3 revenue down 21% to $37.9M; launches strategic review with Goldman Sachs
Q3 2023 revenue $37.9M, down 21% YoY; net loss $50.3M vs $45.3M; Adjusted EBITDA loss $29.8M vs $25.9M.
Adaptive Biotech Q2 revenue up 12% to $48.9M; net loss narrows; MRD chief exits
Revenue $48.9M (+12% YoY); MRD revenue $25.9M (+22%); Immune Medicine $23.0M (+3%).
Director Robert Hershberg fails to win majority support at AGM; Leslie Trigg resigns
Robert Hershberg received 44.02% for, 55.97% withhold/abstain in Class 1 director election; Katey Owen elected with 76.66%.
FDA accepts IND for first neoantigen-directed T-cell therapy from Adaptive-Genentech collaboration
FDA accepted IND for TCR-based T-cell therapy candidate; first from collaboration to enter clinical development.
Adaptive Biotechnologies Q1 net loss $57.7M; clonoSEQ volume up 57% YoY
Revenue $37.6M (-3% YoY); MRD $21.4M (+20%); Immune Medicine $16.2M (-22% due to Genentech amortization decline).
Adaptive Biotech COO Mark Adams terminated; duties absorbed by President Rubinstein
Mark Adams, COO, was informed on April 7, 2023, that his service will be terminated by May 2023.
Adaptive Biotechnologies Q4 revenue $55.2M (+46% YoY); guides FY2023 rev $205M-$215M
Full year 2022 revenue $185.3M (+20% YoY); MRD revenue $87.1M (+32%), Immune Medicine $98.2M (+11%).
Adaptive Biotechnologies Q3 revenue $47.8M (+21% YoY); narrows FY2022 revenue guidance to $185-190M
Q3 2022 revenue $47.8M vs $39.5M in Q3 2021 (+21%); clonoSEQ test volume up 52% YoY.
Adaptive Biotechnologies secures up to $250M non-dilutive royalty financing from OrbiMed
Initial $125M tranche at closing; Adaptive may draw up to $75M more (by Sept 2025) and $50M for M&A (by Sept 2025).
Adaptive Biotech Q2 revenue $43.7M (+13% YoY); MRD up 38%, net loss widens
Revenue $43.7M (+13% YoY); MRD revenue $21.3M (+38%) on 53% test volume growth; Immune Medicine $22.4M (-3%).
Adaptive Biotechnologies Q1 revenue $38.6M (+0.5% YoY); net loss widens to $62.8M
clonoSEQ test volume grew 45% YoY and 12% QoQ; MRD regulatory milestone revenue of $3.0M from partner drug approval.
Adaptive Biotechnologies Q4 revenue +26% to $37.9M; CFO Chad Cohen resigns, interim CFO appointed
Q4 2021 revenue $37.9M (+26% YoY); net loss $61.4M (vs $44.6M). Full year revenue $154.3M (+57%); net loss $207.3M.
Adaptive Biotechnologies guides FY2021 revenue $153M-$154M (+56% YoY); CFO Cohen to resign
FY2021 preliminary revenue $153M-$154M, up ~56% from $98.4M in 2020.
Q3 2021 revenue $39.5M (+50% YoY); sequencing revenue $22.1M (+96%), development revenue $17.4M (+16%).
Adaptive Biotechnologies Q2 revenue $38.5M, +83% YoY; raises FY2021 guidance to $148M-$155M
Revenue $38.5M (+83% YoY); sequencing revenue $18.6M (+132%), development revenue $20.0M (+53%).
As previously announced, Adaptive Biotechnologies Corporation (the “ Company ”) appointed Kyle Piskel, the Company’s Principal Accounting Officer, to serve as its Chief Financial Officer effective April 8, 2024.
Kyle Piskel, who has been with Company for 8 years and is currently its Principal Accounting Officer will serve as the Chief Financial Officer starting on April 8, 2024.
On April 1, 2024, the Chief Financial Officer of Adaptive Biotechnologies Corporation (the “ Company ”) Tycho Peterson submitted his resignation.
On September 1, 2023, Adaptive Biotechnologies Corporation (the “ Company ”) Board of Directors (the “ Board ”) member Kevin Conroy submitted his resignation from the Board.
On July 28, 2023, the Company's Chief Commercial Officer of the MRD business, Nitin Sood, resigned to pursue a new opportunity.
On June 9, 2023, Adaptive Biotechnologies Corporation (the " Company ") Board of Directors (the " Board ") member Leslie Trigg submitted her resignation from the Board.
On April 7, 2023, Mark Adams, Chief Operating Officer of Adaptive Biotechnologies Corporation (the “Company”), was informed that his service is being terminated by May 2023.
On March 9, 2022, the Board of Directors of Adaptive Biotechnologies Corporation (the “ Company ”) appointed Tycho Peterson as Chief Financial Officer of the Company, effective upon his start date, no later than June 4, 2022 (the “ Effective Date ”).
the Board of Directors of the Company appointed Mr. Kyle Piskel, the Company’s Principal Accounting Officer, as interim Chief Financial Officer effective concurrent with Mr. Cohen’s resignation
the Company’s Chief Financial Officer, Mr. Chad Cohen, is resigning effective February 15, 2022
after which Mr. Kyle Piskel, the Company’s Principal Accounting Officer, will act as Chief Financial Officer and principal financial officer.
On January 4, 2022, Chad Cohen, Chief Financial Officer of the Company, notified the Company of his decision to resign as Chief Financial Officer of the Company, effective following the filing of the Company’s Annual Report on Form 10-K for the period ended December 31, 2021, on or about February 15, 2022, after which Mr. Kyle Piskel, the Company’s Principal Accounting Officer, will act as Chief Financial Officer and principal financial officer.
Max materiality 0.80 · Median 0.70 · Most common event earnings